Prevention of Cognitive Decline and Improvement of Innate Immunity in MCI Patients by medical drink containing omega-3 fatty acid and botanical antioxidant

Exciting results from a prospective study in patients with mild cognitive impairment (MCI) who received medical drink containing omega-3 and antioxidant were presented at the CTAD conference in Barcelona this week. The omega-3 antioxidant drinks with vit. D3 in this study was provided by NNN member Smartfish. 

The objective of this was to show that this specific combination of nutrients improves amyloid-beta clearance and prevents cognitive decline in MCI patients.

The lipid modulator from docosahexaenoic acid (DHA) called resolvin D1 (RvD1) and the hormonal form of vitamin D3 (1,25D3) promote amyloid-beta phagocytosis and regulate inflammatory genes in macrophages. Omega-3 fatty acids DHA and EPA are precursors of the lipid modulators resolvins, protectins and maresins that resolve inflammation. Both Alzheimer Disease and MCI patients have macrophages that are defective in phagocytosis and degradation of amyloid-beta.

Results from this study showed that nutritional supplementation of MCI patients with a drink containin omega-3 and antioxidants maintained or improved cognition in Apo E3/E3 genotype patients. The supplementation improved amyloid-beta phagocytosis and regulated macrophage type to M1/M2 pro-phagocytic, mildly inflammatory type. These results suggest that this specific formulation of omega-3/antioxidant can be beneficial in individual MCI patients who are observed and treated in a personalized fashion.

Text above based on abstract and poster from the CTAD (Clinical Trials on Alzheimer's Disease) Conference